Extensive metastatic ependymoma with long-term progression-free survival with capecitabine plus temozolomide combination chemotherapy: A case report

J Cancer Res Ther. 2024 Jul 1;20(5):1625-1627. doi: 10.4103/jcrt.jcrt_1664_22. Epub 2023 May 3.

Abstract

We wanted to present a rare case of metastatic grade 2 spinal ependymoma with an atypical course at the time of diagnosis. Temozolomide plus capecitabine chemotherapy was started in May 2018 on a 30-year-old female patient with sacral ependymoma who had extensive lung metastases at the time of diagnosis. The patient remained in remission for approximately 29 months, and the current chemotherapy was continued until it progressed in November 2020. According to this case report, a combination of temozolomide and capecitabine may be the best treatment option for ependymoma patients.

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
  • Capecitabine* / administration & dosage
  • Capecitabine* / therapeutic use
  • Ependymoma* / drug therapy
  • Ependymoma* / pathology
  • Female
  • Humans
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / pathology
  • Lung Neoplasms / secondary
  • Progression-Free Survival
  • Temozolomide* / administration & dosage
  • Temozolomide* / therapeutic use

Substances

  • Capecitabine
  • Temozolomide